Literature DB >> 14982985

Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study.

Arun K Verma1, Jack H da Silva, David R Kuhl.   

Abstract

BACKGROUND: Furosemide is usually administered by the oral or intravenous route to cardiac patients with hypertension and heart failure, as well as edema. Occasionally, furosemide cannot be administered by these routes.
OBJECTIVE: To evaluate the diuretic/natriuretic efficacy of subcutaneously administered furosemide in healthy volunteers.
METHODS: This single-center, double-blind, placebo-controlled, randomized, crossover pilot study compared the diuretic effect of subcutaneously administered furosemide and NaCl 0.9% (placebo) in 12 healthy volunteers. The study was conducted over 5 days. Baseline values were determined on day 1. On days 3 and 5, each volunteer was injected with either furosemide 20 mg (2 mL) or 2 mL of placebo subcutaneously. A washout period occurred on day 4. Fluid and dietary intake were controlled on all 3 data collection days. Primary outcome measures consisted of urine volume voided, urine sodium concentration, onset time and volume of initial urine output, and number of voids during 8 hours of urine collection.
RESULTS: All outcomes demonstrated statistically significant differences when treatment and placebo groups were compared (p < 0.05). Adverse effects most commonly reported by the participants were minor and included transient burning and stinging at the injection site.
CONCLUSIONS: This study demonstrates that subcutaneously administered furosemide is a viable alternative when the oral or intravenous route of administration is not desirable or possible in humans. However, the results of this study need to be corroborated in various patient populations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982985     DOI: 10.1345/aph.1D332

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  Palliative and end-of-life care for patients with chronic heart failure and chronic lung disease.

Authors:  Miriam J Johnson; Sara Booth
Journal:  Clin Med (Lond)       Date:  2010-06       Impact factor: 2.659

Review 2.  Management of end stage cardiac failure.

Authors:  Miriam J Johnson
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

Review 3.  Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas.

Authors:  Melanie A Jackson; Nicholas Caputo; Jessica R Castle; Larry L David; Charles T Roberts; W Kenneth Ward
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

4.  Mechanisms of glucagon degradation at alkaline pH.

Authors:  Nicholas Caputo; Jessica R Castle; Colin P Bergstrom; Julie M Carroll; Parkash A Bakhtiani; Melanie A Jackson; Charles T Roberts; Larry L David; W Kenneth Ward
Journal:  Peptides       Date:  2013-05-04       Impact factor: 3.750

5.  In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect.

Authors:  W Kenneth Ward; Ryan G Massoud; Cory J Szybala; Julia M Engle; Joseph El Youssef; Julie M Carroll; Charles T Roberts; Richard D DiMarchi
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

Review 6.  Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review.

Authors:  Maxwell Eyram Afari; Joe Aoun; Sarthak Khare; Lana Tsao
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

7.  Dilemmas in the Dosing of Heart Failure Drugs: Titrating Diuretics in Chronic Heart Failure.

Authors:  David Pham; Justin L Grodin
Journal:  Card Fail Rev       Date:  2017-11

8.  Outpatient Worsening Heart Failure as a Target for Therapy: A Review.

Authors:  Stephen J Greene; Robert J Mentz; G Michael Felker
Journal:  JAMA Cardiol       Date:  2018-03-01       Impact factor: 14.676

9.  Discomfort from an alkaline formulation delivered subcutaneously in humans: albumin at pH 7 versus pH 10.

Authors:  W Kenneth Ward; Jessica R Castle; Deborah L Branigan; Ryan G Massoud; Joseph El Youssef
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

10.  Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution.

Authors:  Domenic A Sica; Pieter Muntendam; Rene L Myers; Jozine M Ter Maaten; Mark E Sale; Rudolf A de Boer; Bertram Pitt
Journal:  JACC Basic Transl Sci       Date:  2018-02-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.